狼瘡治療市場：依疾病類型、治療藥物類型、給藥途徑、通路、地區

預計2024年全球狼瘡治療市場規模為32.5億美元，2031年將達59.1億美元，2024年至2031年複合年成長率為8.9%。

圖 1. 2024 年狼瘡治療藥物市場佔有率(%)（按地區）

由於全球狼瘡盛行率不斷上升，全球狼瘡治療市場在過去幾年中穩步成長。狼瘡是一種慢性自體免疫疾病，身體的免疫系統開始攻擊自身的組織和器官。它通常影響育齡婦女，主要症狀包括關節疼痛、皮疹、疲勞和器官發炎。據估計，大約有 150 萬美國人和全世界至少 500 萬人患有狼瘡。政府和醫療組織加強對狼瘡早期診斷和治療藥物的認知活動，進一步推動了市場成長。此外，正在進行的開發更安全、更有效的治療方法的研究也促進了預測期內的市場成長。

市場動態：

全球狼瘡治療市場是由全球狼瘡患病率不斷上升、對狼瘡認知的提高以及醫療保健支出的增加所推動的。據美國狼瘡基金會稱，美國每年報告約 16,000 例新患者。政府對狼瘡治療藥物研發活動的有利支持也促進了市場成長。然而，高昂的藥品成本和器官特異性狼瘡藥物的稀缺性是預計在一定程度上抑制市場成長的一些關鍵因素。同時，正在進行的新型生技藥品和個人化醫療的臨床試驗將為未來幾年的市場進入者提供利潤豐厚的機會。

本研究的主要特點

• 該報告對全球狼瘡治療藥物市場進行了詳細分析，並提供了以2023年為基準年的預測期（2024-2031年）的市場規模（十億美元）和年複合成長率（CAGR%）。
• 它還強調了各個細分市場的潛在收益成長機會，並說明了該市場有吸引力的投資提案矩陣。
• 它還提供了有關市場促進因素、限制因素、機會、新產品發布和核准、市場趨勢、區域前景、主要企業採取的競爭策略等的主要考察。
• 根據公司亮點、產品系列、主要亮點、績效和策略等參數，對全球狼瘡治療藥物市場的主要企業進行概況分析。
• 主要企業包括 Hikma Pharmaceuticals PLC、Dr. Reddy's Laboratories Ltd.、Amgen Inc.、Novartis AG、Sanofi、UCB SA、ImmuPharma PLC、Bayer AG、Merck &Co.、Aurinia Pharmaceuticals Inc.、Pfizer Inc.、AstraZeneca、F.。 Hoffmann-La Roche Ltd.、Bristol-Myers Squibb Company、Teva Pharmaceutical Industries Ltd.、Takeda Pharmaceutical Company Limited 和Boehringer Ingelheim International Gmbh。
• 該報告的見解使負責人和公司經營團隊能夠就未來的產品發布、升級、市場擴張和行銷策略做出明智的決策。
• 全球狼瘡治療藥物市場迎合了該行業的各種相關人員，如投資者、供應商、產品製造商、經銷商、新進業者和財務分析師。
• 相關人員可以透過用於全球狼瘡治療藥物市場分析的各種策略矩陣來促進他們的決策。

目錄

第1章 研究目的與前提

• 研究目標
• 先決條件
• 簡稱

第2章 市場展望

• 報告說明
  • 市場定義和範圍
• 執行概述
• 一致的機會地圖 (COM)

第3章市場動態、法規及趨勢分析

• 市場動態
  • 促進因素
  • 抑制因素
  • 機會
• 影響分析
• 流行病學
• 市場趨勢
• 監管場景
• 製造商收益
• 收購和合作場景
• 產品發布/核准
• 資金籌措和投資
• PEST分析
• 波特的分析

第4章全球狼瘡治療市場 - 冠狀病毒 (COVID-19) 大流行的影響

• 整體影響
• 政府舉措
• COVID-19 對市場的影響

第5章全球狼瘡治療市場，依疾病類型，2019-2031（十億美元）

• 介紹
• 全身性紅斑性狼瘡（SLE）
• 皮膚紅斑狼瘡
• 藥物性紅斑狼瘡
• 新生兒狼瘡

第6章全球狼瘡治療市場，依治療類型，2019-2031（十億美元）

• 介紹
• 非類固醇消炎劑(NSAID)
• 生技藥品
• 抗瘧疾藥
• 皮質類固醇
• 其他

第7章 全球狼瘡治療市場，依給藥途徑，2019-2031 年（十億美元）

• 介紹
• 口服
• 皮下的
• 靜脈
• 其他

第 8 章全球狼瘡治療市場，按分銷管道分類，2019-2031 年（十億美元）

• 介紹
• 醫院藥房
• 醫療用品店
• 其他

第9章全球狼瘡治療市場，按地區，2019-2031（十億美元）

• 介紹
• 拉丁美洲
• 歐洲
• 亞太地區

Global lupus therapeutic market is estimated to be valued at USD 3.25 Bn in 2024 and is expected to reach USD 5.91 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.9% from 2024 to 2031.

Figure 1. Lupus Therapeutic Market Share (%), By Region, 2024

The global lupus therapeutic market has been witnessing steady growth over the past few years owing to the rising prevalence of lupus disease globally. Lupus is a chronic autoimmune disorder where the immune system of the body starts attacking its own tissues and organs. It commonly affects women in their childbearing years and major symptoms include joint pain, rashes, fatigue, and organ inflammation. According to estimates, about 1.5 million Americans and at least 5 million people worldwide suffer from a form of lupus. Growing awareness initiatives by government and healthcare organizations regarding early diagnosis and treatment of lupus has further boosted the market growth. Moreover, ongoing research into developing safer and more effective therapeutic drugs will continue driving the market growth during the forecast period.

Market Dynamics:

The global lupus therapeutic market is driven by the growing prevalence of lupus globally, rising awareness initiatives regarding the disease, and increasing healthcare expenditure. As per the Lupus Foundation of America, around 16,000 new cases are reported in the U.S. every year. Favorable government support for research and development activities focused on lupus therapeutics is also propelling the market growth. However, high treatment cost and lack of drugs for organ-specific lupus are some of the key factors expected to restrain the market growth to a certain extent. On the other hand, ongoing clinical trials for novel biologic drugs and personalized medicine offer lucrative opportunities for market players in the coming years.

Key Features of the Study:

• This report provides an in-depth analysis of the global lupus therapeutic market, and provides market size (USD Bn) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year.
• It elucidates potential revenue growth opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global lupus therapeutic market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this includes Hikma Pharmaceuticals PLC, Dr. Reddy's Laboratories Ltd., Amgen Inc., Novartis AG, Sanofi, UCB S.A., ImmuPharma PLC, Bayer AG, Merck & Co., Inc., Aurinia Pharmaceuticals Inc., Pfizer Inc., AstraZeneca, F.Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Boehringer Ingelheim International Gmbh.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• Global lupus therapeutic market caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global lupus therapeutic market.

Detailed Segmentation-

• By Disease Type:
  • Systemic Lupus Erythematosus (SLE)
  • Cutaneous Lupus Erythematosus
  • Drug-Induced Lupus Erythematosus
  • Neonatal Lupus
• By Treatment Type:
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Biologics
  • Antimalarial Drugs
  • Corticosteroids
  • Others
• By Route of Administration:
  • Oral
  • Subcutaneous
  • Intravenous
  • Others
• By Distribution Channel:
  • Hospital Pharmacies
  • Medical Stores
  • Others
• By Region:
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East
  • Africa
• Company Profiles:
  • Hikma Pharmaceuticals PLC
  • Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB S.A.
  • ImmuPharma PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Disease Type
  • Market Snapshot, By Treatment Type
  • Market Snapshot, By Route of Administration
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Opportunities
• Impact Analysis
• Epidemiology
• Market Trends
• Key Developments
• Regulatory Scenario
• Manufacturer Revenue
• Acquisitions and Partnerships Scenario
• Product Launches/Approvals
• Funding and Investments
• PEST Analysis
• Porter's Analysis

4. Global Lupus Therapeutic Market - Impact of Coronavirus (COVID-19) Pandemic

• Overall Impact
• Government Initiatives
• COVID-19 Impact on the Market

5. Global Lupus Therapeutic Market, By Disease Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Systemic Lupus Erythematosus (SLE)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Cutaneous Lupus Erythematosus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Drug-Induced Lupus Erythematosus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Neonatal Lupus
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

6. Global Lupus Therapeutic Market, By Treatment Type, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Biologics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Antimalarial Drugs
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Corticosteroids
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

7. Global Lupus Therapeutic Market, By Route of Administration, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

8. Global Lupus Therapeutic Market, By Distribution Channel, 2019 - 2031, (USD Bn)

• Overview
  • Market Share Analysis, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, 2019 - 2031
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Medical Stores
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2019-2031, (USD Bn)

9. Global Lupus Therapeutic Market, By Region, 2019 - 2031, (USD Bn)

• Introduction
  • Market Share Analysis, By Region, 2024 and 2031 (%)
  • Y-o-Y Growth Analysis, For Region, 2019-2031
  • Regional Trends
    • North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2019 - 2031, (USD Bn)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2019 - 2031, (USD Bn)
    • U.K.
    • Germany
    • Italy
    • France
    • Spain
    • Russia
    • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
• Middle East
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
  • North Africa
  • Central Africa
  • South Africa

10. Competitive Landscape

• Company Profiles
  • Hikma Pharmaceuticals PLC
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Dr. Reddy's Laboratories Ltd.
  • Amgen Inc.
  • Novartis AG
  • Sanofi
  • UCB S.A.
  • ImmuPharma PLC
  • Bayer AG
  • Merck & Co., Inc.
  • Aurinia Pharmaceuticals Inc.
  • Pfizer Inc.
  • AstraZeneca
  • F.Hoffmann-La Roche Ltd
  • Bristol-Myers Squibb Company
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International Gmbh

11. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

12. References and Research Methodology

• References
• Research Methodology
• About us and Sales Contact